Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Breast and Gynecologic Cancer Research Group

Programs and Projects

Breast Cancer Prevention Clinical Trials


Ongoing Phase I/II Prevention Trials Funded and Monitored by the Breast and Gynecologic Cancer Research Group (BGCRG)

Principal Investigator Funding Mechanism Title of Award Chemopreventive Agent
Carol Fabian, MD**
R01 Breast Cancer Prevention by Letrozole in High Risk Women
NCT00579826
Letrozole
Melanie Palomares, MD**
City of Hope, Beckman Research Institute
R01 Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction
NCT01196936
Tamoxifen
Jose Russo, MD
Fox Chase Cancer Center
R21 Genomic Markers of Breast Cancer Prevention Induced by hCG in Women at High Risk r-hCG
Howard Baily, MD
University of Wisconsin
PhaseI/II Consortia Contract A Randomized, Double-Blind, Single Dose and Multi-Dose Study of the Novel Retinoid, 9cUAB30 to Determine Pharmacokinetics and Safety 9-cis-UAB30
Sherry Chow, PhD
University of Arizona
PhaseI/II Consortia Contract Phase Ib Study of Resveratrol in Postmenopausal Women with High Body Mass Index Resveratrol
Seema Khan, MD**
Northwestern University
PhaseI/II Consortia Contract Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women with Ductal Carcinoma In-situ of the Breast
NCT00952731
Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen
Howard Baily, MD
University of Wisconsin
PhaseI/II Consortia Contract A Pilot Study of the Novel Retinoid, 9cUAB30 to Determine Preliminary Pharmacokinetics
NCT00896974
9-cis-UAB30
Carol Fabian, MD**
University of Kansas Medical Center
PhaseI/II Consortia Contract A Phase II Study of Acolbifene in Premenopausal Women at High Risk for Breast Cancer
NCT00853996
Acolbifene
Banu Arun, MD**
MD Anderson Cancer Center
PhaseI/II Consortia Contract A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
NCT00637481
Atorvastatin
Dawn Hershman, MD
Columbia University
PhaseI/II Consortia Contract Phase 1b Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with a History of Hormone Receptor-Negative Breast Cancer
NCT00516243
Polyphenon E
Ray Bergan, MD
Northwestern University
PhaseI/II Consortia Contract A Phase IIB Trial of G - 2535
(Unconjugated Isoflavones -100) in Women at High Risk Breast Cancer
NCT00290758
G - 2535 (Unconjugated Isoflavones -100)
Placebo
Powel Brown, MD, PhD**
MD Anderson Cancer Center
Monitoring Lapatinib in Treating Women With Ductal Carcinoma In Situ of the Breast
NCT00555152
Lapatinib
Jennifer Eng-Wong, MD
Georgetown University Medical Center
Monitoring Trial of Exemestane in Post-menopausal Women with DCIS or at High Risk for Invasive Breast Cancer
NCT00073073
Exemestane
David Euhus, MD
UT Southwestern Medical Center
Dallas, Texas
Master Agreement An Exploratory Study to Identify Potential Surrogate Endpoint Biomarkers That are Modulated by Tamoxifen vs. Placebo in Women with an Increased Risk for Breast Cancer Tamoxifen


** indicates studies that are open to accrual

Back to top